Compare ATCX & IRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ATCX | IRIX |
|---|---|---|
| Founded | 2016 | 1989 |
| Country | Brazil | United States |
| Employees | 13 | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.8M | 23.2M |
| IPO Year | N/A | 1996 |
| Metric | ATCX | IRIX |
|---|---|---|
| Price | $5.50 | $1.04 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $13.75 | N/A |
| AVG Volume (30 Days) | 33.1K | ★ 161.5K |
| Earning Date | 03-16-2023 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 51.85 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,593,000.00 |
| Revenue This Year | $827,667.00 | $3.07 |
| Revenue Next Year | $166.45 | $6.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.39 | $0.87 |
| 52 Week High | $14.01 | $1.65 |
| Indicator | ATCX | IRIX |
|---|---|---|
| Relative Strength Index (RSI) | 48.42 | 38.17 |
| Support Level | $5.32 | $0.99 |
| Resistance Level | $6.46 | $1.20 |
| Average True Range (ATR) | 0.68 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 48.21 | 38.21 |
Atlas Critical Minerals Corp is a mineral exploration and development company focused on critical minerals projects and properties in Brazil. The company's portfolio principally includes mineral properties for rare earths, graphite, titanium, copper, uranium, and nickel. It also owns mineral rights for iron ore, quartzite, gold, and diamond properties. The company's project portfolio includes the Alto Paranaiba, Malacacheta, Arcos, Goias, Tocantins, Rio Piracicaba, and other projects.
IRIDEX Corp is involved in the business of developing, manufacturing, and marketing laser-based medical systems, delivery devices, and consumable instrumentation for ophthalmology. Its products include Lasers, Laser delivery devices, Glaucoma devices, Retinal surgical instruments, and Veterinary and ENT products. The firm also powers its products with its proprietary Micropulse technology. The company operates in only one reportable segment, Ophthalmology. It derives revenues from the sale of consoles, delivery devices, consumables, services, and support activities. The geographical segments of the company include the United States, which drives maximum revenue, Europe, and the Americas, excluding the U.S. and Asia/Pacific Rim.